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The two major dasses of chemical weapons
are mustard gas and the nerve gases.
Although both types are commonly called
gases, they are actually rather viscous liquids
that are not remarkably volatile. What is
remarkable is that these agents were designed
to harm people by any route ofexposure and
to be effective at low doses. It is also note-
worthy that these major agent classes have
not changed in over 50 years (1,2.
What has changed recently is our percep-
tion of the potency of the chemical agents
(3), the inclusion ofmore women in the mil-
itary, and the likelihood that targets may
include civilians (4). We have also become
concerned with the nonlethal, persistent,
and delayed effects that may be produced
(5-22. These issues are put into better per-
spective with some background knowledge
of the effects of chemical weapons on
humans, particularly via routes of exposure
likely to be encountered following wartime
release.
Mustard
Mustard gas, bis-(2-chloroethyl) sulfide
(Chemical Abstract Service No. 505-60-2),
is also known as mustard, S-mustard, sulfur
mustard, HS, HD, H, Kampstoffe, Lost, S-
Lost, Schwefel-Lost, Y, Yellow Cross, and
Yperite. At 25°C, the vapor pressure, liquid
density, and volatility of mustard are 0.11





Although it is lethal in high doses and affects
multiple organ systems, it is classed as a vesi-
cant (blistering) agent (23,24).
Mustard was first synthesized in the early
or middle 1800s, and its vesicant properties
were understood atthattime (25). Since then,
it has been recognized as a radiomimetic (5)
and a human carcinogen (24,26). It may also
be teratogenic and mutagenic (27,28).
Mustard is an alkylating agent, and once
absorbed, its toxic effects result from chemi-
cal reactions with cellular constituents. These
biochemical reactions cause inhibition of
mitosis, nicotinamide adenine dinucleotide
(NAD) depletion, decreased tissue respira-
tion, and ultimately, cell death (23,24).
The first wartime use ofmustard was by
the Germans against the British at Ypres,
Belgium, on 12July 1917. Its physicochemi-
cal properties made it the chemical agent
mostwidely used duringWorld War I; mus-
tard accounted for approximately 400,000
casualties-almost 77% ofall the gas casual-
ties (29). However, the death rate from mus-
tard exposurewas only about 2% (1,30-32).
Many of the toxicologic properties of
mustard were not appreciated until after
World War I. Approximately 95% of the
men gassed with mustard had respiratory
involvement. Eye lesions were even more
common (33), and many soldiers were tem-
porarily blinded (34). It also became appar-
ent that a one-time exposure to a relatively
high concentration of mustard could result
in chronic or recurring effects (6-10,35).
Respiratory problems were most frequently
observed. However, skin and eye lesions that
had apparently healed recurred spontaneous-
ly decades later (36,31. In addition, soldiers
who had been gassed with mustard seemed
to develop respiratory cancers more fre-
quently than expected (9-11).
Despite the Geneva Convention of1925,
which prohibited the use of chemical
weapons, mustard production continued,
and many countries generated large stock-
piles. During World War II, there were
numerous instances of occupational expo-
sures at various production facilities through-
out the world. Some of these exposures
underscored the insidious nature of mustard
gas. Employees did not realize that they had
been exposed until symptoms developed the
next day (38). Occupational experiences also
indicated that chronic disability could result
from mildly symptomatic exposure to rela-
tively low concentrations for periods as brief
as a few weeks (39-41). Given that mustard
is relatively persistent, such observations are
significant from a wartime perspective in that
people exposed to prolonged off-gassing of
mustard-contaminated material or terrain
could develop chronic respiratory problems.
Occupational exposures have also under-
scored the carcinogenic and mutagenic
potential ofmustard in humans (40-50).
Although it smells like garlic or mustard,
disabling vapor concentrations may have so
little odor that one is not aware ofthe dan-
ger until hours after exposure, when signs
and symptoms begin to appear (24,25,51).
Mustard does not cause pain upon contact,
and there is a latent period before effects
begin to occur.
This aspect of mustard is graphically
underscored by the incident at Bari Harbor,
Italy, in 1944. Although mustard was not
used offensively, a number of casualties
occurred when an Allied ship loaded with
mustard-filled munitions was sunk in a
German bombing. The destroyer Bistera was
in the harbor when the bombing occurred,
and it participated in the rescue work. It is
unknown whether the crewmembers were
directly, but unwittingly, exposed to a mus-
tard cloud or iftheywere exposed bythe off-
gassing ofmustard-contaminated individuals
who had been rescued from the harbor. The
following is quoted directly from Alexander
(52,53).
After picking up about thirty casualties, the har-
bor was ordered cleared and the Bisteraput to sea
for Taranto. Four to six hours out of Bari, eye
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symptoms began to develop in the ship's officers
and most of the crew. The commanding officer
ordered immediate irrigation of everyone's eyes
with an eye wash, but the symptoms continued
to increase in severity. It was only with great dif-
ficulty that the ship was brought into Taranto
harbor eighteen hours later, as the staffand crew
were practically blinded by their acute eye
lesions. These eyes cleared up rapidly and com-
pletely, but they did require hospitalization.
Following World War II, approximately
52,000 tons of mustard were dumped into
the Baltic Sea; many fishermen have been
exposed vwhen they accidentally hauled up
mustard-filled munitions and containers. As
recently as 1984, 23 Baltic fishermen were
exposed to mustard when they netted some
mustard-filled shells that had been dumped
into the ocean (23,54). Several ofthese fish-
ermen were reported to have a significant
increase in sister chromatid exchanges
(SCEs) (55). SCEs are the result ofbreaking
and rejoining of chromosomes and can be
caused byalkylation ofDNA.
Since World War I, mustard has been
allegedly used by the following: Great Britain
in the Middle East; the French in Morocco;
Italy against Ethiopia in 1936; Japan against
China in 1937; Poland against Germany in
1939; the Russians in Central Asia; Egypt
against Yemen from 1963 to 1967; Iraq
against Iran during the Iran-Iraq War, and
Iraq against the Kurds (1,12,23,24,30). The
findings in mustard-exposed Iranian soldiers
are similar to those reported during World
War I: eye and skin lesions, with more severe
cases having respiratory and gastrointestinal
problems (56-58).
Mustard is fat soluble and is readily
absorbed through exposed tissues. The
effects of mustard intoxication can be local,
systemic, or both, depending on the route,
extent, and duration of exposure, and may
include one or more target organs. The sys-
temic effects include bone-marrow inhibi-
tion with consequent reduction in the num-
ber of white cells and damage to the gas-
trointestinal tract. Local effects occur at
much lower dosages than systemic effects,
and exposure to airborne concentrations of
mustard is unlikely to produce systemic
effects in the absence of severe local effects
on the eyes and respiratory tract (24).
There is a latent period ofup to 24 hr or
more between exposure and the onset of
effects. Onset time is a function of dosage:
higher dosages tend to produce more severe
effects with shorter latent periods (59). Full-
blown effects may not be manifest for several
days (51). The latency period for eye injury is
shorter than that for injury caused by equiva-
lent dosages elsewhere on the body (24).
Moderate ocular effects can be pro-
duced without knowledge ofexposure. Low
concentrations of vapor produce lachryma-
tion and conjunctival injection. The present-
ing symptom is often a feeling of grittiness
or the sensation that something is in the
eyes. Higher concentrations produce corneal
damage, photophobia, and blepharospasm.
Any liquid mustard splashed into the eye is
likely to result in blindness (60). Even in the
absence of permanent ocular lesions, mus-
tard vapor exposure produces temporary
blindness, and ocular effects are those most
likely to incapacitate the soldier.
By acute inhalation, mustard can
produce sneezing, rhinorrhea, nosebleed,
pharyngitis, hoarseness, coughing, bronchitis,
tracheitis, tracheobronchitis, tachypnea, and
pseudomembrane formation with subsequent
pneumonia (24). Mild exposure damages the
laryngeal and tracheobronchial mucosa.
Moderate exposure causes hyperemia and
necrosis of the mucous membranes of the
respiratory tract. Severe exposure produces
necrosis, exudation, and the formation of
diphtherialike pseudomembranes. Recent
human data indicate that the most common-
lydamaged parts ofthe respiratory system are
the large airways, but in severe cases the
lower airways and lung parenchyma are also
affected (61). Any inhalation exposure pro-
duces lesions that predispose the individual
to bronchopneumonia (62). Pneumonia may
be accompanied by loss ofappetite, diarrhea,
fever, and apathy (63). Pneumonia was the
proximal cause of death in the majority of
mustard victims during World War I (24).
Borak and Sidell (32) ascribed death to a
combination of respiratory failure and bone
marrow suppression. Similar findings were
reported following the Iran-Iraq War (61).
If there is respiratory and ocular protec-
tion, the skin is then the target tissue for
airborne mustard (64, and the skin is the pri-
mary target for liquid mustard. With relative-
ly low doses, skin effects are limited to the
exposed tissue. At higher doses, surrounding
areas also become involved. The initial effect
is often erythema, which can be likened to a
sunburn, and is usually accompanied by pain
and edema. Pruritis may precede or accompa-
ny the erythema or persist after it has sub-
sided. Sloughing of the skin may occur fol-
lowing erythema (65). At higher doses vesica-
tion occurs and may be preceded or accompa-
nied by nausea and vomiting and malaise.
Vesication begins with the appearance ofpin-
point vesicles that ultimately coalesce to form
blisters (51). When blisters are present, care
must be taken to prevent infection. Blisters
may be large and painful and take months to
heal. Once healed, the blistered skin may be
hypopigmented or hyperpigmented (66).
Very high doses of mustard may produce
necrosis without vesication (67). The most
sensitive areas ofthe body, those areas burned
at the lowest concentrations and mostseverely
burned overall, are the axillae and genitals
(25,58,66). Borak and Sidell (32) reported
that nearly half ofthe American survivors of
World War I mustard gas attacks had scrotal
and perianal burns. The severity of effects
(and presumably penetration and absorption)
are strongly mediated by ambient tempera-
ture and humidity, increases ofwhich exacer-
bate the human response by decreasing the
effective dose (24).
The current medical countermeasures for
acute mustard exposure are essentially those
developed during World War I: symptomatic
treatment combined with antibiotics to pre-
vent secondary infections in damaged mem-
branes (1,68). Although systemic effects are
manifest only athigherdoses, it has been esti-
mated that 80-90% ofmustard gas penetrat-
ing the skin rapidly passes into the circulation
(691. Ifthe exposed area is not decontaminat-
ed within a matter of 15 min or less, there is
no way to prevent the subsequent effects
(24,25,70-73).
Despite the extensive human database on
mustard, many questions remain. The effects
ofbattlefield exposure to mustard have been
well described, but the doses that produce
them are unknown and may have resulted
from prolonged or repeated exposures.
Controlled human studies on effective doses
of mustard were carried out from approxi-
mately 1918 to the mid-1960s (12,34,65,74)
and were typically conducted to determine
the acute effects from relatively brief expo-
sures. Some of the stated effective doses for
these studies are somewhat conflicting
(62,65). Given the analytical chemistry tech-
niques and experimental methodology of
those times, the level of precision associated
with the reported vapor concentrations may
have been less than optimal. Nonetheless, the
larger body of available mustard data does
not address manyofthe toxicologic questions
being askedtoday.
Nerve Agents
The nerve gases or nerve agents are all fluo-
rine- or cyanide-containing organophos-
phates (OPs) similar to insecticides. They are
the most potent of the known chemical
agents, are rapidly lethal, and are hazardous
by any route of exposure. The nerve agent
0-ethyl S-[2-(diisopropyamino)ethyl]-
methylphosphonothioate (VX) is estimated
to be 103-104 times more potent than the
more potent commercially available OP
insecticides (75). It is theoretically possible
to disseminate the nerve gases in high
enough vapor concentrations that one breath
would be incapacitating ordeadly (76).
Nerve agents are generally grouped into
two classes: G and V (Table 1). G agents are
derivatives of phosphoramidocyanidic or
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methylphosphonofluoridic acid and indude
sarin (GB; isopropyl methylphosphono fluo-
ridate), tabun (GA; ethyl N-dimethylphos-
phoramidocyanidate), soman (GD; pinacolyl
methylphosphonofluoridate), and GF (o-
cyclohexyl-methyl-fluorophosphonate). V
agents are derivatives of methylphospho-
nothioic acid (77). VX is the primaryV-type
agent. The relative potencies of the nerve
agents are VX > GD = GF > GB > GA
(13,77). VX is the least volatile and the most
potent. Although it is often perceived to be
more of a percutaneous threat, VX poses a
serious hazard ifvolatilized. By comparison,
G agents do not present much of a contact
hazard (78). Any liquid nerve agent splashed
into the eyes is potentially lethal (30).
The first G agent, GA, was synthesized
by the German scientist Gerhard Schrader
(Leverkusen Laboratories, I.G., Farben-
industrie) in 1936. GB was synthesized
about a year later (7$). Other G agents were
developed around the time ofWorldWar II,
and the V-type agents were developed about
1950 (80). Although Germany had manu-
factured, munitionized, and stockpiled as
much as 30,000 tons of GA and GB, they
were not used during World War II. In fact,
the Allies were not aware of these agents
until several key German facilities were cap-
tured (30,80).
Our lack of knowledge of the nerve
agents was graphically demonstrated in one
ofthe initial experiences with captured GA.
One- and 2-mm drops ofGA were put onto
test subjects to determine ifit was avesicant;
the results were negative. A 1-mm drop was
then placed into the eye ofa rabbit to deter-
mine if the substance was designed to cause
eye damage. The animal rapidly went into
convulsions and died (30).
Nerve agents bind covalently to the
enzyme acetylcholinesterase (AChE), irre-
versibly inhibiting it and causing accumula-
tion ofacetylcholine (ACh) at neuroeffector
junctions in the peripheral and central ner-
vous systems (14,79,81). Similarly, nerve
agents inhibit the blood cholinesterases
(ChEs), but these are not the targets oftoxi-
city and are of unknown function (13).
There is poor correlation between toxic signs
and symptoms, dose, and degree of blood
ChE inhibition (13,79,82-85). Repeated
small exposures can suppress virtually all the
blood ChE activity while producing only
negligible clinical effects (82,86). However,
inhibition ofblood ChE is often an excellent
indicator ofnerve agent (or other anti-ChE)
exposure, and clinical signs-other than
local effects-are unlikely to occur in the
absence ofinhibition ofblood ChE.
The clinical signs and symptoms of
nerve agent intoxication are caused by
cholinergic overstimulation resulting from
ACh accumulation (87,88). Severe intoxica-
tion is manifested by salivation, involuntary
defecation and urination, sweating, lacrima-
tion, bradycardia and hypotension, respira-
tory depression, collapse, convulsions, and
death (13). The proximal cause of death is
respiratory failure.
Vapor inhalation with concomitant ocu-
lar vapor exposure is the most effective and
most likely route ofadministration, especial-
ly for the more volatile agents. The effects
that occur at the lowest airborne vapor con-
centrations are miosis, rhinorrhea, and tight
chest. These are direct local effects and can
occur in the absence ofany measurable inhi-
bition ofblood ChE (13,86).
Nerve agents also affect the nicotinic
ACh receptor-ion channel complexes and
bind to cardiac M2 receptors, but it is not
clear that these effects occur at physiologic
concentrations in vivo. Likewise, nerve agent-
induced effects on gamma amino butyric
acid (GABA)-ergic systems may be implicat-
ed in seizure activity at high doses (80).
Contrary to some OP insecticides, the
nerve agents do not inhibit neurotoxic
esterase at physiologic concentrations. OP-
induced delayed neuropathy (OPIDN) is
unlikely to occur except at doses greatly
exceeding the median lethal dose (LD50)
(13,80,89-91).
There have been allegations of military
use of nerve agents by Iraq against Iranian
soldiers and in combination with mustard
against Kurdish civilians (1,80). These agents
have been used by terrorists on civilian popu-
lations inJapan, and there was an accidental
release ofVX in a remote area ofthe United
States. No human injuries were reported, but
6,300 sheep were affected and 4,500 were
directly killed by the agent or were required
to be euthanized (92,93). There has been no
large-scale military useofnerve agents.
Our knowledge of the human effects of
nerve agents is based on human and animal
studies, most ofwhich were done to deter-
mine acute effects for brief exposures.
Controlled human studies ofvery low doses
were conducted from the 1940s to the 1980s
(15,30). Accidental exposures of chemical
agent workers and use of chemical weapons
by terrorists have also contributed to the
body of human data. Animal studies date
from the 1940s to the present. In the older
studies, many ofthe reported vapor concen-
trations are nominal, and analytical data,
when available, were crude by today's stan-
dards. In some cases, review of the original
data indicates that reported nominal vapor
concentrations, when analytical data were
also available, were 1.33-1.67% of the ana-
lytical concentrations. This means that the
actual effective dosages may have been some-
what less than those reported (13). Some
human exposures and other experiences with
nerve agents will be briefly discussed to
underscore the potency, severity, and rapidity
ofaction ofthese chemicals.
As reported by Sidell (94), a worker in a
nerve agent-contaminated area was wearing
full protective gear while cleaning an area
contaminated with GB. Upon later investiga-
tion it was discovered that the "voicemitter"
diaphragm on his gas mask was cracked. He
began to complain of increased oronasal
secretions and difficulty breathing, and left
the area. The worker quickly developed
marked respiratory distress with copious
secretions. Although he arrived at the emer-
gency room within 5-10 min of his first
symptoms, he was cyanotic and convulsing.
His breathing was labored and he had mus-
cular fasciculations, miosis, marked saliva-
tion, and rhinorrhea. He was treated with
atropine and pralidoxime but required
mechanical ventilation. Abnormalities in his
electrocardiogram precipitated subsequent
hospitalization elsewhere. Following recovery,
theworkerexperienced aprolonged period of
Table 1. Physical and chemical properties of nerve agents.
Properties Sarin (GB) Tabun (GA) Soman (GD) GF VX
CH3 0 0 CH3 0 CH3 0 °
Structural formula CH-0-P-F C2H50-P-N CH3-P-O-C-C(CH3)3 CH3-P-O0 CH3-P-S-CH2CH2-N-[CH(CH3)212
CH3 CH3 CN CH3 F H F OCH2CH3
CAS no. 107-44-8 77-81-6 96-64-0 329-99-7 50782-69-9
Liquid density at25°C 1.09 g/mL 1.08g/mL 1.02g/mL 1.13 g/mL 1.0083 g/mL
Volatility at25°C 2.2 x 104mg/m3 610mg/mr3 3900mg/m3 581 mg/m3 10.5mg/m3
Vapor pressure at 25°C 2.9mmHg 0.07mmHg 0.40mmHg 0.044mmHg 0.0007 mmHg
Abbreviations: CAS, Chemical AbstractService; GF, o-cyclohexyl-methylfluorophosphonate; VX, 0-ethyl S-[2-(diisopropylamino)ethyllmethylphosphonothioate.
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mental depression, possibly attributable to
the nerve agent. Approximately 18 months
after exposure, he died from a myocardial
infarction. Autopsy confirmed severe coro-
nary artery disease. It is possible that the ini-
tial abnormalities on the electrocardiogram
may have resulted from a myocardial infarc-
tion and not from the direct effects of the
GB on cardiac tissue (13).
In June of 1994, a terrorist group released
C(B into a civilian population in Matsumoto,
Japan. The most severely affected survivor
noted blurring of his vision after opening a
window. He went to bed 2 hr later and was
found unconscious the next day. Seven people
were killed, and 600 were affected; 58 were
admitted to hospitals (16,17).
On 20 March 1995, the same terrorist
group released liquid GB in parcels in the
Tokyo subway at rush hour. Twelve people
were killed and over 5,000 required emer-
gency medical evaluation (18). Most of the
exposed individuals presented with miosis,
and many had headaches. More than half
experienced respiratory difficulties and nat-
sea. Many others experienced eye pain,
blurred vision, dim vision, rhinorrhea, and
vomiting. About 17% were categorized as
moderately toxic, a category that included all
symptoms through convulsions as long as
mechanical ventilation was not required.
The average hospital stay for this group was
2.4 days. Less than 1% were severely affect-
ed, but all required mechanical ventilation
and were hospitalized for more than a week
(18). If the agent had been actively dissemi-
nated, the number and severity of casualties
would have been significantly higher. People
who were near the liquid-filled parcels or
who were contaminated with liquid received
the highest doses. Some fatalities were docu-
mented (16,18).
Early human studies with GJA tested
dosages of0.7-30 mg/min/m3 (2- to 10-min
exposures; some individuals had ocular or res-
piratory protection). Observed effects ranged
from tight chest at the lowest dosages to mio-
sis, frontal headache, retrobulbar pain, ocular
erythema, rhinorrhea, nausea and vomiting,
tight chest, blurred vision, sleep disturbances,
lassitude, and visual changes, some of which
persisted for over aweek (13,30).
Some studies with GB have shown 100%
miosis and tight chest at dosages as low as 0.6
mg/min/m3 (1min exposure; analytical con-
centration). Higher dosages produced marked
visual symptoms and frontal headache. Other
human exposures to GB vapor indicate that
dosages > 15 mg/min/m (1.i5-mn exposure)
produce a marked fall in blood AChE, with
concomitant pronounced symptoms of sys-
temic nerve gas poisoning including general-
ized weakness, nausea and vomiting, and eye
and respiratory effects. This dosage has
been suggested as the lower limit ofphysical
incapacitation (13).
It is well documented that recovery from
miosis can take days or weeks (79). Recovery
ofChE activity can take months (87,95,96).
It has also been reported that electroen-
cephalogram and electromyogram abnormal-
ities can persist for over a year and are some-
times not demonstrable without highly
sophisticated techniques (15,19-22,79).
This perspective was potentially corroborat-
ed by the Tokyo incident. Epileptiform elec-
troencephalograms were observed in two
individuals and persisted for 11 months in
one; neither had clinical seizure activity (17).
The significance of these effects is not well
understood (22), and more data are needed
before the determination can be made that
these changes do not represent adverse
effects (14,30,97. Psychiatric sequelae have
also been reported after anti-ChE poisoning
and may be more common after severe
intoxication than currently thought (94).
Morphologic brain damage has been
observed in animals surviving prolonged
seizures. Marrs et al. (30) consider it "proba-
ble that both histopathological changes and
functional deficits" would be observed in
humans surviving sublethal doses.
Safety considerations have impacted the
body of data for most of the nerve agents,
particularly GD and VX. [GD is refractory
to oxime treatment (30) and VX is extremely
potent.] Such considerations have also
impacted experimental paradigms, and many
human and animal studies have employed
noninhalation routes of administration,
despite the fact that vapor inhalation is usu-
ally the most probable route of exposure.
Although the effects produced by the nerve
agents are somewhat independent of the
route ofexposure, the order of their appear-
ance and their clinical importance are very
much a function of the route of exposure.
Percutaneous exposure will not produce
miosis unless the exposure is severe enough
to produce systemic effects (80). When this
is the case, the median effective dose (ED50)
for miosis is not significantly different from
the LD50; one may be prostrate, convulsing,
and moribund before miosis occurs (98).
Clearly, the effects of nerve agent intoxi-
cation can be local, systemic, or both,
depending on the dose and the route ofexpo-
sure. However, it is difficult, if not impossi-
ble, to delineate doses that fall into a specific
category of effect. The dose-response curves
for the nerve agents are very steep. Given this
and their potency, the transition from local
to systemic effects can be quite abrupt. Doses
producing severe effects are not significantly
different from those that are lethal (13).
Following vapor inhalation, local effects
includc tracheobronchial constriction,
excessive secretions, and paralysis of the
diaphragm and other respiratory muscles.
Central effects include paralysis of the auto-
nomic function in the brainstem. Respiratory
failure can be central, peripheral, or a combi-
nation of the two (99,100). The predomi-
nant site of failure is a functioni of the route
ofexposure and the species. Vapor inhalation
produces airway obstruction secondary to
excessive secretions and bronchoconstriction,
and peripheral neuromuscular weakness and
respiratory paralysis are likely to predominate
(13,79,101).
With systemic absorption, the effects of
nerve agents on the central nervous system
(CNS) include drowsiness, difficulty concen-
trating, emotional lability, sleep distur-
bances, excessive dreaming and nightmares.
depression, lassitude, irritability, loss of
libido, memory loss, and difficulty concen-
trating. Many of these can occur at very low
doses. More severe effects include collapse,
prostration, convulsions, respiratory failure,
and death (13,20,87). Other systemic effects
include nausea and vomiting, hypermotility
of the lower bowel, and involuntary urina-
tion (87). Percutaneous effects are local
effects and include localized sweating and
muscular fasciculation in the immediate
vicinity ofagent contact.
Changes in Perspectives on the
Hazards of Chemical Weapons
Recent reviews of the available toxicologic
data for chemical weapons (3) have recom-
mended downward revisions in some of the
human toxicity estimates for military person-
nel for mustard and the nerve agents. It is
important to understand why our perception
ofthe potency ofthese chemicals has changed
and to comprehend some of the factors that
impact the effective doses ofchemical agents.
Most ofthe available toxicologic data and
concomitant human toxicity estimates were
generated when the chemical weapons were
beingdeveloped. The purpose ofmanystudies
was to determine which chemicals rapidly pro-
duced severe, acute effects at the lowest doses.
Likewise, many of the human toxicity esti-
mates were developed from the perspective of
how quickly such effects were produced in the
least sensitive, healthy, male soldier (3). Given
that the time to effect is inversely proportional
to the dose, the apparent time to effect was
reduced by making the estimated doses larger
than necessary to produce the specified end
points. Even for mustard, the human esti-
mates were intended to reduce the normal
latency period of > 1 day to a few hours for
the development offull-blown effects.
Sex and body size were not a concern
when the chemical weapons were being
developed, and potential sex differences are
nor well characterized in the animal data.
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Given the makeup ofthe military at the time,
the subjects in the controlled human studies
were fit, relatively young male soldiers, and
the majority ofthe reported accidental expo-
sures also involved men (30,83,102.
This has changed. Potential targets
include women in military and civilian pop-
ulations (4). There is also concern over sub-
lethal effects produced by relatively low
doses over relatively long exposure periods
(12-18). There are few such data, particular-
lyfor appropriate exposure routes.
Based upon both sex and weight, differ-
ences have been anticipated in the sensitivity
ofwomen to chemical agents as compared to
men (3). Studies have shown sex and hor-
monal effects on peripheral ChE (103). A
recent review (13) conduded thatsuch differ-
ences are likely, and they may be route- and
agent-dependent; the most marked findings
are via inhalation exposure. In the latter case,
females were twice as sensitive as males to GB
(13). When civilians become military targets,
age, health, and sex factor into the sensitivity
of the population. Diverse civilian popula-
tions will be more sensitive than a population
of healthy adult workers or soldiers. Some
studies have indicated as much as a 10-fold
difference (104). Therefore, it should not be
assumed that human toxicity estimates
derived for male soldiers are applicable to
female soldiers, and it should be assumed
that a civilian population would be more sen-
sitive than amilitarypopulation.
Sublethal effects were not end points of
concern when the nerve agents were being
developed. The intentwas toproduce incapac-
itation or death very quickly after a relatively
briefexposure to a rather high concentration.
Similarly, with mustard gas the aim was to
produce very severe effects as quickly as possi-
ble. Given this and the physical properties of
the agents, toxicologic studies were conducted
accordingly. Sublethal effects were typically
not the toxicologic end points ofanimal stud-
ies, particularly for nerve agents. Further,
some of the less severe effects in humans
(nausea, vomiting, headaches, nightmares,
visual degradation, involuntary urination,
depression, amnesia, malaise) are difficult to
discern in many laboratory species. Although
the human exposures were done at sublethal
levels, they do not encompass the spectrum
between doses that produce very mild effects
and those that are just sublethal, nor were
they done from the perspective ofeffects pro-
duced by very low doses received over a peri-
od ofhours or days (30). As a result, there are
still many unknowns in the linearity of the
dose-response curves ofthe agents over time.
Haber's Law is not valid for the nerve agents,
even for exposure durations ranging from
2-10 min, and there are fewdata available for
longer exposures (3,13). For some agents it is
very clear that higher concentrations for a
short exposure are more effective than lower
concentrations for alonger exposure duration;
the dosage in milligrams per minute per cubic
meter increases as exposure time increases
(13). For other agents the converse may be
true. Similarly, few studies have been done
with mustard to delineate this concentra-
tion-time relationship.
Summary
The two major threat classes of chemical
weapons are mustard gas and the nerve
agents. Mustard was used in World War I,
and there is an extensive human database on
it. The fact that mustard gas is a carcinogen
and readily produces a variety of chronic or
persistent effects was not fully appreciated
until after the war and following extensive
human occupational exposure prior to World
War II. The nerve agents were developed
shortly before, during, and after World War
II. Nerve agents can be rapidly lethal, and the
experimental human database is considerably
more limited than that for mustard. Also,
there has been no large-scale military use of
nerve gas. It has, however, been used by ter-
rorists on civilian populations. Nerve agents
may produce histopathological changes in
the CNS and electrophysiologic changes in
the CNS and the peripheral nervous system.
Many of the toxicologic studies and human
toxicity estimates for both mustard and the
nerve agents were generated for the purpose
of developing chemical agents that would
quickly produce maximal casualties in the
least sensitive male soldier. Today our con-
cern is the objective estimation ofdoses and
effects for the typical soldier, both male and
female. We must also consider the effects of
chemical agents on civilian populations and
the effects ofprolonged exposures to relative-
ly low doses (105). The questions being
asked are different than those for which the
historical data were generated. These materi-
als have always been extremely potent and
efficacious. Their toxicity has not changed,
but ourperception ofit has.
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